The stock of GSK plc (NYSE:GSK) increased by $0.11 on Monday to finish at $35.44, up 0.31 percent. The last five days have seen an average of 3,164,500 shares of common stock traded. 11 times new highs were reached in the current year, with a gain of $0.30. The average number of shares traded over the last 20 days was 2,976,225, while the average volume over the last 50 days totaled 3,243,000.
GSK stock appreciated 2.64% since last month. On 08/03/23, the company’s shares reached a one-month low of $33.97. The stock touched a high of $39.74 on 04/13/23, after rallying from a low of $28.47 in 52 weeks. The price of GSK stock has risen by 0.85% or $0.30 this year, reaching a new high 11 times. Still, the stock price is down -10.82% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
GSK plc (GSK) has a trailing price-to-earnings (P/E) ratio of 10.67. Beta for the stock is 0.69. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.95, the price-to-book (PB) ratio of 4.46, and the price-to-cash flow ratio of 20.61.
Company paid $0.3613 per share in dividends, an increase of 3.97% from $0.3475 last year. A $0.0137 dividend increase was reported on Wednesday July 26 2023.
Financial Health
For the three months ended June 29, GSK plc’s quick ratio was 0.60, while its current ratio was 0.90, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.23, and the total debt to equity ratio is 1.69. As far as profitability goes, gross margin for the trailing twelve months is 71.50% percent. GSK plc’s EBITDA margin for the year ended June 29 was 30.11%, whereas its operating margin stood at 24.80% for the same period. Based on annual data, it had gross profit of $24.45 billion and revenue of $36.27 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GSK’s return on assets (ROA) during the last 12 months has been 25.90%. There was a 18.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 139.40%.
Earnings Surprise
According to GSK plc’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $29.32 billion, while revenues fell by -16.33% to $0.0. It was predicted that GSK plc’s quarterly earnings would be $0.97, but it ended up being $0.87, beating the consensus by 11.50%. EBITDA was $3.27 billion for the quarter. At the end of GSK plc’s most recent quarter ended June 29, its liabilities totaled 59.23 billion, while its total debt was $21.47 billion.
Technical Picture
Here’s a quick look at GSK plc’s (GSK) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 59.16%, suggesting the stock is Neutral, with a 12.00% historical volatility rate.
The stochastic %K and %D were 54.50% and 50.48% respectively, while the average true range (ATR) was 0.48. Based on the 14-day stochastic reading of 61.00%, the RSI (14) reading is 55.37%. On the 9-day MACD Oscillator, the stock is at 0.41, and the 14-day reading is at 0.18.
Analyst Ratings
In its analyst report released on July 14, 2023, HSBC Securities began covering GSK plc (NYSE: GSK). The stock was rated as a Reduce by the brokerage firm. Analysts have assigned GSK plc (GSK) an Hold rating. GSK is a stock that is recommended for selling by 3 brokerage firms, while 11 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.
What is GSK’s price target for the next 12 months?
The current consensus forecast for the stock is between $30.62 and $66.47, with a median target price of $39.61. In analyzing these forecasts, the average price target given by analysts for GSK plc (GSK) is $42.44.
